Latest News and Press Releases

JAMA Dermatology published the positive results from a pivotal Phase 3 study evaluating the efficacy and safety of ZORYVE® (roflumilast) foam 0.3%

OAKLAND, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Patients who struggle with opioid addiction and who are treated by California emergency department physicians are remarkably successful at...

New study shows Chronic Obstructive Pulmonary Disease (COPD) increasing globally through 2050, with 47% growth among women.

Memphis, TN, March 09, 2023 (GLOBE NEWSWIRE) -- Memphis-based Baptist Cancer Center published a JAMA Network Open article proving the effectiveness of incidental lung nodule, or tumor, programs in...

Roflumilast cream showed higher efficacy compared to vehicle in both Phase 3 studies on the primary efficacy endpoint of Investigator Global Assessment (IGA) success, with 40% of roflumilast cream...

LOS ANGELES, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...

GAITHERSBURG, Md., Aug. 06, 2019 (GLOBE NEWSWIRE) -- GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc.,  and a recognized leader in genetic and genomic testing, announced the results...

New York, NY, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Building on research that established the first large-scale normative cardiac data set for basketball players (and athletes of similar size as elite...

PORTLAND, OR--(Marketwired - Jul 14, 2015) - Today, Jama Software -- a cloud-based collaborative solution used by enterprises worldwide to define, build and test software and technology products --...

OTTAWA, Feb. 3, 2015 (GLOBE NEWSWIRE) -- A new study published in JAMA Internal Medicine identifies significant barriers to discussions about care for seriously ill patients in Canadian hospitals. The...